New options for the treatment of patients with uncontrolled course of chronic rhinosinusitis with nasal polyps with dupilumab: a clinical case
- Autores: Moiseeva Y.P1, Piskunov G.Z1, Kosyakov S.Y.1, Kirsanova A.A1, Shaikhutdinova E.F1
-
Afiliações:
- Russian Medical Academy of Continuous Professional Education
- Edição: Volume 29, Nº 5 (2022)
- Páginas: 70-76
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321005
- DOI: https://doi.org/10.18565/pharmateca.2022.5.70-75
- ID: 321005
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Sobre autores
Yu. Moiseeva
Russian Medical Academy of Continuous Professional Education
Email: md_moiseeva@mail.ru
Moscow, Russia
G. Piskunov
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
S. Kosyakov
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
A. Kirsanova
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
E. Shaikhutdinova
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
Bibliografia
- Рязанцев С.В., Лопатин А.С., Пискунов Г.З., и др. Клинические рекомендации «Полипозный риносинусит». М.-СПб. 2014. 20 с. @@Ryazantsev S.V, Lopatin A.S., Piskunov G.Z., et al. Clinical guidelines «Polypous rhinosinusitis». M.-SPb. 2014. 20 p. (In Russ.)
- Fokkens W.J. Phenotyping, endotyping and clinical decision-making. Rhinology. 2016;54(2):97-8. doi: 10.4193/Rhin.543E2.
- Bachert C., Han J.K., Desrosiers M., et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-50. doi: 10.1016/S0140-6736(19)3 1881-1.
- Fokkens W.J., Lund V., Bachert C., et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312-doi: 10.1111/all.13875. Epub 2019 Jul 15.
- Fokkens W.J, Lund V.J., Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.
- Alobid I, Bernal-Sprekelsen M., Mullol J. Chronic rhinosinusitis and nasal polyps: The role of generic and specific questionnaires on assessing its impact on patient's quality of life. Allergy Eur J Allergy Clin Immunol. 2008;63(10):1267-79. Doi: 10.111 1/j. 1398-9995.2008. 01828.x.
- Пискунов Г.З. Полипоз носа, околоносовых пазух и его лечение. Российская ринология. 2003;2:10-13. @@Piskunov G.Z. Polyposis of the nose, paranasal sinuses and its treatment. Rossiiskaya rinologiya. 2003;2:10-13. (In Russ.).
- Bohman A, Juodakis J, Oscarsson M, Bacelis J, Bende M, Torinsson Naluai A. A family-based genome-wide association study of chronic rhinosinusitis with nasal polyps implicates several genes in the disease pathogenesis. PLoS One. 2017 Dec 18;12(12):e0185244. Doi: 10.1371/ journal.pone.0185244.
- Hopkins C. Chronic rhinosinusitis with nasal polyps. N Engl J Med. 2019;381(1):55-63. doi: 10.1056/NEJMcp1800215.
- Wynn R., Har-El G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2004;114(5):811-13.
- Vlaminck S., Vauterin T., Hellings P.W, et al. The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: A 3-year prospective observational study. Am J Rhinol Allergy. 2014;28(3):260-64.
- De Greve G., Hellings P.W., Fokkens W.J, et al. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7(1).22. doi: 10.1186/s13601-017-0157-8.
- Laidlaw T.M., Buchheit K.M. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2020;124(4):326-32.
- Lanzillotta M., Campochiaro C., Trimarchi M., et al. Deconstructing IgG4-related disease involvement of midline structures: Comparison to common mimickers. Mod Rheumatol. 2017;27(4):638-45. doi: 10.1080/14397595.2016.1227026.
- Bachert C., Mannent L., Naclerio R.M., et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial. JAMA. 2016;315(5):469-79. Doi: 10.1001/ jama.2015.19330.
- Frampton J.E., Blair H.A. Dupilumab: a review in moderate to severe atopic dermatitis. Am J Clin Dermatol. 2018;19(4):617-24. Doi: 10.1007/ s40257-018-0370-9.
- Rabe K.F, Nair P., Brusselle G., et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(2 6):2475-85. Doi: 10.1056/ NEJMoa1804093.
- Wenzel S., Ford L., Pearlman D., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455-2466. doi: 10.1056/NEJMoa1304048.
- Trimarchi M., Bellini C., Fabiano B., et al. Multiple mucosal involvement in cicatricial pemphigoid. Acta Otorhinolaryngol Ital. 2009;29(4):222-25.
- Trimarchi M., Bondi S., Della Torre E., et al. Palate perforation differentiates cocaine-induced midline destructive lesions from granulomatosis with polyangiitis. Acta Otorhinolaryngol Ital. 2017;37(4):281-85. doi: 10.14639/0392-100X-1586.
- Trimarchi M., Indelicato P., Vinciguerra A., Bussi M. Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial. Clin Case Rep. 2021;9(3):1428-32. doi: 10.1002/ccr3.3792.